Pimozide — a commonly used antipsychotic drug — has been shown to be effective for the treatment of triple negative breast cancer, an aggressive form of breast cancer which is difficult to treat, according to a new study published in the journal Oncotarget.
Professor Mohamed El-Tanani from the University of Bradford, Bradford, UK, and colleagues conducted the study to investigate whether Pimozide inhibits cancer cell growth in vitro and results in DNA damage.
The study also showed that the drug, Pimozide, has the potential to treat the most common type of lung cancer.
Anti-psychotic drugs are known to have anti-cancer properties, with some, albeit inconclusive, studies showing a reduced incidence of cancer amongst people with schizophrenia. The present study is the first to identify how one of these drugs acts against triple negative breast cancer, with the potential to be the first targeted treatment for the disease.
“Triple-negative breast cancer has lower survival rates and increased risk of recurrence. It is the only type of breast cancer for which only limited targeted treatments are available. Our research has shown that Pimozide could potentially fill this gap. And because this drug is already in clinical use, it could move quickly into clinical trials.” said El-Tanani.
The researchers, from the University of Bradford, Queen’s University Belfast and the University of Salamanca, tested Pimozide in the laboratory on triple negative breast cancer cells, non-small cell lung cancer cells and normal breast cells.
They then tested the drug on mice implanted with triple negative breast cancer.
- At the highest dosage used, up to 90 percent of the cancer cells died following treatment with the drug, compared with only five percent of the normal cells.
- Tumors in mice treated with Pimozide were 65 percent smaller than in untreated mice and the number of tumors reduced by up to 61 percent.
- The drug also helped to prevent cancer from spreading: treated mice had up to 94 percent fewer metastases in the lung than mice who didn’t receive Pimozide.
The drug involved in the research wasn’t chosen at random. Previous research by Professor El-Tanani has shown that a certain protein, called Ran-GTP, plays a significant role in enabling the growth and spread of a number of cancers, including triple negative breast cancer.
When Professor El-Tanani mapped thousands of existing drugs against this protein, to identify which would be most effective in blocking Ran-GTP, Pimozide came top of the table. He then worked with colleagues to test the drug in cells and mice and identify the mechanisms by which the drug, and the inhibition of Ran-GTP, were affecting cancer.
The study found that, in addition to reducing proliferation of triple negative breast cancer cells and increasing the percentage of cells that died, the drug was able to reduce migration and invasion of these cancer cells. It suppressed production of a protein, called VEGFR2, that supports blood supply to tumors, prevented the production of an enzyme that is linked to metastasis and prevented the production of cells called myofibroblasts that help promote tumor growth.
“There are many molecular pathways that are hyperactive in cancer,” explained Professor El-Tanani. “Our study shows that by acting as a Ran-GTP inhibitor, Pimozide was able to block a number of key pathways that contribute to triple negative breast cancer growing and spreading.”
Now the team have proven the effectiveness of this drug in vitro and in vivo, a patent has been applied for and they are actively seeking funding to move to clinical trials, to test its impact in humans.
“Pimozide might inhibit tumor development by suppressing angiogenesis and by paracrine stimulation provided by host reactive stromal cells. These results demonstrate a novel in vitro and in vivo antitumor activity of Pimozide against breast and lung cancer cells and provide the proof of concept for a putative Pimozide as a novel approach for cancer therapy,” concluded the authors.
For further reference follow the link: https://doi.org/10.18632/oncotarget.26175